Freeox Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

FreeOx Biotech is a Spanish, private, late-stage clinical company developing Ox-01, a novel adjunct therapy for Acute Ischemic Stroke (AIS). The drug, which is pharmaceutical-grade Uric Acid, aims to improve patient outcomes when administered alongside the current standard-of-care, Mechanical Thrombectomy. Its promising efficacy was uniquely highlighted in a rigorous NIH/NINDS preclinical network study (SPAN), positioning it as a leading candidate to address a major unmet need in stroke care. The company is now preparing for a pivotal Phase III trial to confirm these benefits in humans.

NeurologyCerebrovascular

Technology Platform

Therapeutic application of pharmaceutical-grade Uric Acid as a neuroprotective and reperfusion-boosting agent for the brain's microcirculation following ischemic stroke.

Opportunities

Ox-01 addresses the critical unmet need of improving functional independence for the 50% of Mechanical Thrombectomy patients who currently have poor outcomes, targeting a global patient population of millions.

Validation from the prestigious NIH/NINDS SPAN network provides exceptional credibility for fundraising, partnership discussions, and ultimately, market adoption if approved.

The therapy could generate significant value for healthcare systems by reducing the long-term care costs associated with dependent stroke survivors.

Risk Factors

The company faces high clinical risk as its entire value depends on a single Phase III trial in a challenging indication, where previous neuroprotective agents have repeatedly failed.

As a private, pre-revenue company, it is vulnerable to financing risks and may struggle to fund the expensive pivotal trial.

Regulatory hurdles and the need to change emergency clinical practice patterns pose significant commercialization risks even with approval.

Competitive Landscape

FreeOx's primary competition is the current standard of care: Mechanical Thrombectomy alone. Direct competition in the specific niche of MT-adjunct neuroprotectants is limited, as the SPAN study found other candidates ineffective. However, it competes broadly with other stroke therapeutic approaches in development and faces potential future competition from new devices or drugs. Its strongest advantage is the unique NIH-backed preclinical efficacy data.

More companies in Small Molecule Drugs →More companies in Spain →